To identify novel therapeutic targets for non-small cell lung cancer (NSCLC), we conducted an integrative study in the following 3 stages: (i) identification of potential target gene(s) through shRNA functional screens in 2 independent NSCLC cell lines; (ii) validation of the clinical relevance of identified gene(s) using public databases; and (iii) investigation of therapeutic potential of targeting the identified gene (s) in vitro. A semi-genome-wide shRNA screen was performed in NCI-H358 cells, and was integrated with data from our previous screen in NCI-H460 cells. Among genes identified in shRNA screens, 24 were present in both NCI-H358 and NCI-H460 cells and were considered potential targets. Among the genes, we focused on eIF2b, which is a subunit of heterotrimeric G protein EIF2 and functions as a transcription initiation factor. The eIF2b protein is highly expressed in lung cancer cell lines compared with normal bronchial epithelial cells, and gene copy number analyses revealed that eIF2b is amplified in a subset of NSCLC cell lines. Gene expression analysis using The Cancer Genome Atlas (TCGA) dataset revealed that eIF2b expression is significantly upregulated in lung cancer tissues compared with corresponding normal lung tissues. Furthermore, high eIF2b expression was correlated with poor survival in patients with lung adenocarcinoma, as shown in other cohorts using publicly available online tools. RNAi-mediated depletion of eIF2b suppresses growth of lung cancer cells independently of p53 mutation status, in part through G1 cell cycle arrest. Our data suggest that eIF2b is a therapeutic target for lung cancer.
| INTRODUCTION
Lung cancer is one of the most lethal types of cancers, causing mortality of over 1.5 million people worldwide a year.
1,2 Substantial progress in treatment outcomes for this disease has been made in the past decade, primarily reflecting improved efficacy of molecular targeted drugs. 3, 4 However, long-term survival of advanced lung cancer patients remains very rare, warranting the development of novel therapeutics that specifically target lung cancer cells. We recently performed a semi-genome wide shRNA screen in the non-small cell lung cancer (NSCLC) cell line NCI-H460 and identified therapeutic targets using gene expression and copy number data for lung cancer cells from publicly available sources or experiments in our laboratory. 5 In these studies, we identified proteasome subunit alpha 6 (PSAM6), which encodes a subunit gene of the 26S proteasome complex. Silencing of PSAM6 induced apoptosis or cell cycle arrest in lung cancer cells but not in immortalized normal human bronchial epithelial cells. In addition, PSAM6 was amplified in a subset of lung cancer cell lines, suggesting potential as a therapeutic target for lung cancer.
In addition to PSMA6, we identified several other genes with potential as targets. To delineate optimal therapeutic targets among these genes, we repeated shRNA screens using the alternative NSCLC cell line NCI-H358, and identified 24 genes for which silencing caused growth suppression in both cell lines. In particular, eIF2b (also known as EIF2S2) is a subunit of heterotrimeric G protein EIF2, which comprises the 3 subunits eIF2a, eIF2b and eIF2c. 6, 7 In gene ontology analyses that included the well-studied therapeutic targets for human cancer RAN member RAS oncogene family and exportin 1 (XPO1), [8] [9] [10] [11] we showed that eIF2b is an RNA transport molecule and demonstrated its potential as a therapeutic target.
EIF2 regulates the earliest step of translation in a guanosine triphosphate (GTP)-dependent manner, and binding to GTP but not GDP on the eIF2c promoter initiates translation by delivering an initiator methionyl-tRNA to the ribosome. Switching from the GTP-bound form to the GDP-bound form is mediated by the guanine nucleotide exchange factor EIF2B, which is a heterodecameric complex. In addition, EIF2B activity is inhibited by phosphorylation of Ser51, leading to global repression of translation and concomitant upregulation of several genes that are involved in stress responses. Oncogenic roles of eIF2a have been extensively studied in several human cancers; 6, 12 however, few studies demonstrate the roles of eIF2b in carcinogenesis. For example, in a mouse model of testicular germ cell tumor development, heterozygous deletion of eIF2b reduced the incidence of TGCT. 13 In addition, an integrated genomic search of novel therapeutic targets for breast cancer indicated that eIF2b is highly amplified in luminal breast tumors, which are an aggressive subtype of breast tumors. 14 These studies warrant consideration of eIF2b as a target for lung cancer. Thus, to evaluate the potential of eIF2b-targeted therapy,
we investigated the roles of eIF2b in lung cancer development. We found high eIF2b expression in NSCLC tumors, and that eIF2b was correlated with poor prognosis in patients with adenocarcinoma. Furthermore, eIF2b RNA interference manipulations induced G1 cell cycle arrest in part by upregulating p21
. The present data suggest that eIF2b is a diagnostic and prognostic biomarker for lung cancer and that eIF2b-targeted therapeutics are promising. 
| MATERIALS AND METHODS

| Cell cultures
| Western blot analysis
Western blot analyses were performed using whole cell lysates as described previously. 17 Primary antibodies included rabbit polyclonal anti-actin (Sigma-Aldrich), rabbit monoclonal anti-eIF2b, rabbit mono- 
| Cell cycle analysis
Cells were harvested at 48 hours after transfection with siRNA and were then washed in ice-cold PBS. Following centrifugation at 300 g for 3 minutes, cells were suspended in 300 lL of cold PBS with gentle vortexing before fixing by drop-wise addition of 700 lL of icecold ethanol. Fixed cells were then stored at 4°C for at least 2 hour.
Pelleted cells were washed twice in cold PBS, re-suspended in 1 mL of PBS containing 200 lg/mL RNase and then stained with 20 lg propidium iodide. Cells were then incubated at 37°C for 30 minutes and were maintained at 4°C until analysis. Cells were finally filtered through a 40-lm nylon mesh and were analyzed using a flow FACS Gallios Flow Cytometer (Beckman Coulter, Brea, CA, USA).
| Statistical analysis
All statistical analyses of in vitro data were conducted using IBM SPSS version 23 software (International Business Machines, Armonk, New York, USA) and differences between groups were identified using Mann-Whitney U tests.
Categorical data were compared using Fisher's exact or v 2 -tests.
Continuous variables were compared using Mann-Whitney U tests or paired t tests. Pearson's correlations were used to assess linear associations between variables. Survival data were analyzed using likelihood ratio tests in multivariate analyses. Statistical analyses were performed using JMP (version 13) and GraphPad Prism software (Version 7.0) and differences and correlations were considered significant when P < .05.
Kaplan-Meier survival curves were generated from 474 lung adenocarcinoma samples and available survival data from TCGA (http://ca ncergenome.nih.gov/). Differences in survival were identified using the log-rank test and overall survival was defined as the time from the initial pathological diagnosis (the TCGA dataset) to the date of death or last follow-up, at which point the data were censored. Cox proportional hazards model analyses were performed to adjust for significant covariates in univariate analysis, which included sex, age, smoking status, stage and eIF2b expression, and to estimate relative hazards of F I G U R E 1 Semi-genome-wide screening with a pooled shRNA library identified genes that are essential for proliferation and/or survival of the NCI-H358 lung cancer cells. A, Screening results are presented as a volcano plot with 5043 genes ranked by fold change and significance. Thirty-seven genes are selected as potential candidates based on significant average suppressive effects (P < .05) below a log 2 of À1.5 (red rectangle). B, The Venn diagram shows 3 categories of genes that were identified as targets only in H460, only in H358, and in both H460 and H358 cells mortality over the follow-up period. Finally, mRNA expression levels of eIF2b in the TCGA dataset were dichotomized.
3 | RESULTS 3.1 | Overlapping genes in 2 dropout viability screens of 2 non-small cell lung cancer cell lines were identified as potential targets for lung cancer Previously, we identified candidate genes that have potential as targets for lung cancer using dropout viability screens with an shRNA library and the highly proliferative lung cancer cell line NIC-H460. 5 To select genes that have more generalized potential as therapeutic targets, we initially repeated shRNA screens using the alternative NSCLC cell line H358. We selected this cell line because it differs in the status of p53 from H460; H460 has wild-type p53 while H358 is null for p53. 18 We expected that screens using 2 lung cancer cell lines with or without p53 would enable us to identify therapeutic targets that are not strongly associated with p53 status. H358 cells were lentivirally transduced with the DECIPHER library human Module 1 and abundances of individual shRNA constructs for each gene were quantified by sequencing corresponding barcode sequences using nextgeneration sequencing as described previously. 5 Using a volcano plot ( Figure 1A) we then selected 37 genes as potential candidates based on significant average suppressive effects (P < .05) below a log 2 of À1.5. In our previous study, we arbitrarily employed a cutoff for fold screens to limit the number of targets and used a less stringent foldchange criteria of log 2 = À1.5 for both H460 and H358. These analyses revealed 24 genes that were present in both screens with H460
and H358 ( Figure 1B and Table 1 ). Gene ontology and KEGG pathways for these 24 genes were then performed using the web-based online pathway tool NIH-DAVID (Table 1) . 19, 20 Among KEGG pathways for the 24 genes, the RNA transport pathway was attractive as a therapeutic target because it included XPO1 and RAN, which are well characterized therapeutic targets for human cancers, including lung cancer. [8] [9] [10] [11] Our screening studies identified eIF2b as an additional gene of the RNA transport pathway. This gene encodes the b-subunit of EIF2, which is a heterotrimeric G protein comprising a-, b-and c-subunits, and functions as a translation initiator factor.
| The eIF2b gene is highly expressed in lung cancers and is correlated with poor prognosis of patients with lung adenocarcinoma
We evaluated protein expression levels of eIF2b in a panel of lung cancer cell lines and in 3 cdk4/hTERT-immortalized human bronchial epithelial cell lines with or without the oncogene KRAS
V12
, and compared these with primary NHBE (Figure 2A ). The eIF2b protein was more abundantly expressed in all lung cancer cell lines than in NHBE cells. Thus, to determine whether abundant eIF2b expression follows gene copy amplifications, we evaluated gene copy numbers using array comparative genomic hybridization, and showed that eIF2b is amplified in a subset of NSCLC cell lines (11.6%; cutoff was set as >0.2) (Figure 2B ). We found a moderate correlation between gene copy numbers and protein levels in selected cell lines (Pearson correlation coefficient = 0.6155, P = .0085; Figure S1 ), suggesting that gene copy amplification causes high eIF2b protein expression in some cases.
To determine the clinical relevance of eIF2b in lung cancers, we examined eIF2b expression in lung adenocarcinoma tissue using TCGA dataset. These analyses showed significantly higher eIF2b mRNA expression in lung adenocarcinoma tissues than in normal adjacent tissues, (P < .0001, Mann-Whitney test and paired t test) ( Figure 3A) .
Moreover, eIF2b mRNA levels in 118 (24.9%) of 474 lung adenocarcinomas exceeded the highest expression levels in normal adjacent tissues (Table 2) , and we defined these 118 cases as belonging to the high eIF2b expression group and the other 356 cases to the low group ( Figure S2 ). The level of eIF2b expression in lung adenocarcinomas was significantly associated with gender (P = .0142, Fisher's exact test) and smoking status (P = .0460, v 2 test), but not with age or stage ( Table 2) .
Kaplan-Meier analyses of 474 lung adenocarcinoma patients revealed that high eIF2b expression was significantly associated with worse overall survival (log-rank test P = .0176; Figure 3B ). Furthermore, univariate Cox regression analyses revealed that eIF2b expression and stage were significantly associated with overall survival (P = .0225, HR = 1.96, 95% CI 1.07-2.36; Table 3), and multivariable Cox regression analysis identified eIF2b as a significant independent predictor of overall survival (P = .0255, HR = 1.6-1, 95% CI 1.06-2.41; Table 3 ). To confirm the prognostic potential of eIF2b, we used the online Kaplan-Meier plotter (www.kmplot.com/lung) and PrognoScan (http://www.abren.net/PrognoScan-cgi/PrognoScan.cgi) in a large set of lung adenocarcinomas. Lung adenocarcinoma cases with high eIF2b expression in Kaplan-Meier plots had significantly worse outcomes (log-rank test P = .0076, multivariate analysis P = .0076, HR = 1.4, 95% CI 1.09-1.78; Figure 3C ). Moreover, all 5 lung adenocarcinoma datasets from PrognoScan showed correlations between high eIF2b expression and worse overall survival, and these were significant in 2 datasets ( Figure 3D ).
3.3 | Depletion of eIF2b induced G1 cell cycle arrest, reflecting upregulation of p21 WAF1/CIP1 in lung cancer cells
In further analyses, we examined the effects of eIF2b knockdown on the growth of the non-small cell lung cancer cell lines H460 and H1975. H460 cells were used in our previous shRNA screen and efficient knockdown of eIF2b by RNA interference was confirmed by western blotting ( Figure 4A ). Colorimetric growth assays and colony formation assay showed that eIF2b knockdown in H460 and H1975 suppresses cell growth and colony formation ( Figure 4A,B) .
We also examined the effects of eIF2b knockdown on the growth of HBEC. eIF2b knockdown moderately suppresses cell growth of HBEC ( Figure S3 ). Next, to examine the effects of eIF2b knockdown on in vivo growth of lung cancer cells, we established 2 eIF2b shRNA-expressing H460 subclones that expressed lower levels of eIF2b protein ( Figure S4 ). However, because of drastic growth inhibition by eIF2b knockdown in both subclones, we were unable to subcutaneously inject them into an immunodepleted mouse.
To investigate the growth suppressing mechanisms of eIF2b knockdown, we evaluated changes in cell cycle distribution and apoptosis after eIF2b knockdown. In cell cycle analyses, eIF2b knockdown-induced G1 arrest and decreased numbers of H460 and H1975 cells in the S-phase ( Figure 4C ). In addition, p21 F I G U R E 3 Expression of eIF2b predicts survival in lung adenocarcinoma patients. A, Left graph showing expression levels of eIF2b mRNA in lung adenocarcinoma tumors (n = 512) and adjacent normal tissues (n = 58) in the TCGA dataset; P-values were calculated using the MannWhitney U test. Right graph showing expression levels of eIF2b mRNA in 57 pairs of lung adenocarcinoma tumors and adjacent normal tissues from the same subjects; P-values were calculated using paired t tests. B, Kaplan-Meier survival curves of lung adenocarcinoma patients in the TCGA dataset were stratified according to mRNA expression of eIF2b (eIF2b low, n = 356; eIF2b high, n = 118). C, Kaplan-Meier survival curves of lung adenocarcinoma patients in the dataset of the online Kaplan-Meier plotter were stratified according to mRNA expression of eIF2b (eIF2b low, n = 540; eIF2b high, n = 180). D, Kaplan-Meier survival curves of lung adenocarcinoma in 5 datasets of PrognoScan were stratified according to mRNA expression of eIF2b. In panels (C), (D) and (E) P-values were calculated using log-rank tests. All statistical tests were 2-sided TANAKA ET AL.
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protein expression was increased following eIF2b knockdown in H1975 but not in H460 cells ( Figure 4D ). Because H460 but not H1975 carries wild-type p53, 18 we concluded that eIF2b
knockdown-induced G1 arrest occurred regardless of p53 status. In subsequent western blot analyses of cleaved PARP, no increase in apoptosis were observed in H460 or H1975 cells ( Figure 4D ). , cleaved PARP, phosphoEIF2a and ATF4 in H460, and H1975 cells transfected with eIF2b siRNA or control oligos Hence, eIF2b knockdown-induced growth inhibition of lung cancers occur primarily through G1 arrest, and involves upregulation of p21 WAF1/CIP1 in some cases.
Following stresses, such as endoplasmic reticulum stress, cells reduce the translation-initiation activity of EIF2 to activate antiproliferative pathways, primarily by phosphorylating serine 51 of the a-subunit of EIF2 (eIF2a) and specifically upregulating stress response genes such as ATF4. Thus, we examined whether the eIF2a-S51P-ATF4
pathway is involved in eIF2b knockdown-induced G1 arrest by evaluating phosphorylation of eIF2a and ATF4 expression. Knockdown of eIF2b did not affect either expression of phosphorylation of eIF2a and ATF4 in both H460 H1975 cells ( Figure 4D ). These data indicate that the eIF2a-S51P-ATF4 axis is not involved in eIF2b knockdowninduced G1 arrest in lung cancer cells.
| DISCUSSION
Using the TCGA database with large numbers of samples we show that eIF2b is upregulated in lung cancer tissues. Moreover, upregulation of eIF2b was correlated with worse prognosis in patients with adenocarcinoma, and this was validated in several independent cohorts using publicly available online tools. Many previous studies
show that eIF2a is upregulated in several types of human cancers, including lung cancers, compared with their normal counterparts. 21 Rosenwald et al previously demonstrated that eIF2a is frequently increased in bronchioalveolar carcinomas but not in squamous cell carcinomas. 22 We observed a weak correlation between eIF2a and eIF2b expression ( Figure S5 ), suggesting that simultaneous upregulation of these molecules increases translation initiation, contributing to enhanced proliferation of tumor cells. Alternatively, contributions of upregulated eIF2a and eIF2b to tumorigenesis may be more complicated, because upregulation of eIF2a does not necessarily reflect increased translation-initiation activity. The phosphorylated form of eIF2a lacks global translation-initiation activity, and instead promotes antiproliferative pathways. 6 Therefore, to determine whether upregulation of eIF2a reflects enhanced proliferation of lung cancer cells, precise quantification of phosphorylated and unphosphorylated forms of eIF2a are required in lung tumor tissues.
During the preparation of this manuscript, Salton et al 23 showed that a dominant negative form of eIF2b suppresses proliferation in human embryonic kidney 293 cells through G2 cell cycle arrest. We show that RNAi-mediated silencing of eIF2b suppresses growth of lung cancer cells, in part through G1 arrest, and due to upregulation of p21 WAF1/CIP1 in some cases. Upon eIF2b knockdown, G1 arrest was induced in both p53 wild-type H460 and p53 mutant H1975 cells, 18 suggesting that G1 arrest is induced independently of p53. Differing methods for suppressing eIF2b function result in cell cycle arrest at different phases; whereas the dominant negative form of eIF2b causes G2 arrest in HEK293 cells, RNA interference-mediated eIF2b knockdown results in G1 arrest in lung cancer cells. Although these discrepancies are incomprehensible, differences in cellular contexts and/or unidentified functions of dominant negative eIF2b may influence the outcomes of eIF2b suppression.
Finally, we hypothesize that eIF2b knockdown interrupts the balance between GTP-binding EIF2 (active) and GDP-binding EIF2
(inactive), which may activate the eIF2a-S51P-ATF4 pathway and promote G1 arrest in lung cancer cells. However, eIF2b
knockdown did not significantly affect eIF2a-S51P-ATF4 signaling.
Alternatively, eIF2b knockdown is likely to reduce the availability of GTP-binding EIF2, which may cause G1 arrest, although further experiments are required to support this hypothesis.
In conclusion, eIF2b was highly expressed in the present lung cancer cells and was associated with poor prognoses of patients with adenocarcinoma. In agreement, eIF2b knockdown caused G1 arrest in multiple lung cancer cell lines, suggesting potential as a therapeutic target and prognostic marker.
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